PYX Resources: Achieving volume and diversification milestones. Watch the video here.
Covid results gives the potential of having revenues coming in 2 years earlier than originally planned, plus main market listing and an exciting pipeline with growth potential will determine the price in the end and not the daily shenanigans with the Nasdaq
if he purchased say £300k worth at this close to the results it may of said that its a cert and without a RNS update it would look too obvious. IMO he said last week he wasn't concerned where the price is and this buy is to back up his words.Not long to go now so we will see
14 more trading days till year end plus 1 day closed for New Year so if any news is going to come before the New Year then that's the time left.
NDA = Nasdaq Down Again
Yes I know but as its been mentioned then if that was a possibility as some may think then IMO if any of the NDA data is disclosed to major investors it would still be protected in a Non Disclosure Agreement
Data
The date of an NDA new drug application IMO would be incorporated inside a Non Disclosure Agreement NDA
https://www.fda.gov/drugs/types-applications/new-drug-application-nda
When seeking major investment the Institutional Investors would have had to sign a NDA to have access to more in depth information of the companies products, pipeline financials etc ( business snapshot) and the company would want to protect their information hence the agreement but im sure these investors wouldn't have handed over £57M without this information being available and the confidence to support their decision to take their offer at £2 a share. Any delays or concerns will be addressed with them separately and not in the update call last week and for PIs they have to rely on that call for now and IMO its still better than if any delays were in an RNS.
this guide has some useful information and may give some a better understanding of the IPO challenges and requirements for biotech/pharma companies
https://www.bakermckenzie.com/en-/media/files/insight/guides/2019/guide-to-ipos_biotech-and-pharma.pdf
Foralumab is not a vaccine its a treatment
The covid vaccine news is more of an over reaction against our share and others similar but the market also knows the importance of monoclonal antibodies in this pandemic as these vaccines can not be administrated to everyone such as pregnant women and others. Also they don't know if you can still spread the virus post vaccination, so there's definitely a need for them . With positive results in a few weeks we should see momentum swing our way and gain some important publicity and much needed share price recovery
IMO I think there's room for praise and criticism because the investors call I think was to tell investors of a slight delay and to curb expectations of anything exciting happening before q1 2021. I think the praise is that they didn't RNS this because the share price could have been affected more than where we are now. All other questions were expected but I think this was the main message they wanted to get out with minimal share price damage and I do think they are concerned more than GC may say but just addressing things in a less sensitive way hence the call and no RNS.
They spoke about some assistance such as big Pharma was available but they are trying to avoid using it, now would that include extra funding for scaling up production?
GC stated that it was a proof of concept trial in Brazil so does this equate to P2 or P3
https://youtu.be/WdzTeZxXDjY
https://youtu.be/KcoP5t0NzV4 I thought that Phase 3 trials had already been completed of Foralumab and it was oven ready . The covid situation gave them an opportunity 2 years earlier than planned to show its effectiveness and that's the purpose of the trials in Brazil
So what’s the next RNS update saying ? All plans are on schedule
So there has to be a larger scale trial after this one to seek FDA approval
Alll of the vaccines can carry possible mild side effects such as sore arm, fatigue etc and maybe Foralumab may carry some mild ones too but nothing too serious to prevent the regulators from passing them. Most work on an 50% plus approval when regulators scrutinise the data so 95% for Pfizer vaccine give more confidence on its effectiveness and safety .As for the first approval you may find that the government needed this vaccine out fast because the Oxford Astrazeneca vaccine that they ordered 100m doses faces another trial due to questions over its results and this saves them extra embarrassment.
Even if there's good news from Brazil, we still need to have the main market listing in place, so im hoping for an official trading start date too.
Could be a news update RNS out before the investors call and he's responding to that.